After years of backbiting, practitioners of kyphoplasty and vertebroplasty have finally found an issue upon which they can agree. They need a randomized controlled clinical trial.
Heated exchanges and finger-pointing for alleged clinical flops are the norm between the two camps. However, there is simply no credible evidence to rate one technique above the other for management of osteoporotic vertebral compression fractures, said Dr. Avery J. Evans, an associate professor of radiology and neurosurgery at the University of Virginia, at a special focus session at the RSNA meeting.
Physicians recognize that each technique has shortcomings. For instance, patients undergoing vertebroplasty for fractures caused by tumors seem to have higher complication rates. Some data also suggest that increased vertebral pressure following these interventions can cause new vertebral fractures. Most available references on these procedures, however, come from in vitro biomechanical data, incidental or anecdotal reports, or retrospective, nonrandomized studies.
"Physicians cannot establish the success or complication rate of either technique without a randomized controlled trial," Evans said.
Overall risks seem similar. But the multiple factors influencing the outcome of each procedure have not been properly addressed, said Dr. David F. Kallmes, an interventional neuroradiologist at the Mayo Clinic in Minnesota.
"Until these issues are clearly resolved, we need to have an honest discussion with patients about these procedures," he said. "And we also need to make sure we do our best to manage the disease, not just the symptoms. We definitely need a trial."
Several groups in the U.S. and Canada have set up protocols for prospective studies. The first multicenter randomized controlled trial with a significant patient population is expected to be announced this year.
Breast MRI and Background Parenchymal Enhancement: What a Meta-Analysis Reveals
May 29th 2025Moderate or marked background parenchymal enhancement (BPE) reduces the sensitivity and specificity of MRI for breast cancer detection by more than 10 percent in comparison to scans with minimal or mild BPE, according to a new meta-analysis.
Lunit Unveils Enhanced AI-Powered CXR Software Update
May 28th 2025The Lunit Insight CXR4 update reportedly offers new features such as current-prior comparison of chest X-rays (CXRs), acute bone fracture detection and a 99.5 percent negative predictive value (NPV) for identifying normal CXRs.